Actualités et Activités de Otsuka Holdings

Otsuka Holdings fait partie des...

• Forbes Global 2000 (#654);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Otsuka Holdings est une société cotée sous le symbole boursier 4578 (JP).

Otsuka Holdings a une présence directe dans 11 pays.

Otsuka Holdings a 23 filiales dont Araris Biotech, Cambridge Isotope Laboratories et Interpharma.

Elles sont en:

• Pharmacie46%
• Équipements médicaux29%
• Autre25%

Voir l'organigramme avec ses 263 principaux dirigeants

Biographies les plus recherchées chez Otsuka Holdings

• Makoto Inoue, President and Representative Director, Chief Execut...
• Yukio Matsutani, Independent Director
• Jiro Seguchi, Outside Director and Board Member

Créer une alerte
pour suivre les mouvements de dirigeants chez Otsuka Holdings.

Otsuka Holdings a 3 498 concurrents dont UnitedHealth Group (Etats—Unis), Kaiser Permanente (Etats—Unis) et HCA (Etats—Unis).

Actualités en fusion/acquisition en Santé.

• Hims & Hers a acquis Eucalyptus (publié le 2 juin 2026).
• Freeman Health System a acquis Northwest Health (publié le 2 juin 2026).
• Garner Health vient d'annoncer une levée de fonds de 100 millions de dollars. (publié le 29 mai 2026).

Contacts en Santé

• Ari Bousbib - Chairman and Chief Executive Officer chez IQVIA
• Gregory Adams - Chief Executive Officer and Chairman of the Board chez Kaiser Permanente
• Pablo Legorreta - Chairman of the Board, Founder and Chief Executive Officer chez Royalty Pharma

En savoir plus sur le secteur Santé

Derniers communiqués de presse par Otsuka Holdings

• Otsuka Signs Joint Research Agreement with Keio UniversityIndustry-academia collaboration for infrastructure development toward the social implementation of psychedelics in Japan ｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Pharmavite Established a New Facility in Ohio, US, Dedicated to The Manufacturing of Gummy SupplementsFacilitating the Research and Development of Gummy Products｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Opens First POCARI SWEAT Factory in VietnamSupporting Health and Meeting Growing Demand｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical is Focusing on "Water, Nutrition, and Oxygen" to Tap into Human PotentialProvide "Wellness Energy" at Expo 2025 in Osaka, Kansai, Japan｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical is Expanding "Local Production and Local Recycling" of PET Bottle Initiatives in Cooperation with Local CommunitiesAgreement Signed with the Saga Eastern Environmental Facilities Association for Horizontal Recycling of PET Bottle｜New
• Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Is Now on Sale - Insurance coverage begins on March 1, 2025｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Finalizes an Agreement with Fukuroi City on the Horizontal Recycling of PET BottlesPartnering with Its Factory to Promote a "Local Production and Local Recycling" Initiative for PET Bottles｜News Releases | Otsuka Pharmaceutical Co.,
• Otsuka Sponsor TOKYO MARATHON 2025 Supporting the Conditioning of Runners Worldwide with the Global Brand POCARI SWEAT｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Voir plus de communiqués de presse Close

Réseaux sociaux à propos de Otsuka Holdings

• Otsuka Holdings sur Wikipédia, Google News & Yahoo Finance en 1-click
• Otsuka Holdings sur LinkedIn, X (Twitter) & YouTube en 1-click